TACT

Disease site: Breast Cancer

Treatment Modality: Chemotherapy

Status: In active follow-up

The TACT trial is a randomised trial of standard anthracycline-based chemotherapy (fluorouracil, epirubicin and cyclophosphamide (FEC) or epirubicin and CMF (Epi-CMF)) versus FEC followed by sequential docetaxel in women with early breast cancer. 

4162 patients were recruited between February 2001 and June 2003 from 103 UK centres and 1 Belgian centre. Patients were randomised following written informed consent. Patient assessment of quality of life (QOL) and a health economic analysis form an integral part of the trial. The QOL study was conducted in a sub-set of centres. Tumour tissue was collected prospectively for subsequent biological studies, and blood DNA has been requested from all patients. 

Trial results were presented at the San Antonio Breast Cancer Symposium in December 2007 when 90% of the predefined number of events had been reported. Follow up continues and a manuscript is currently being written.